<DOC>
	<DOC>NCT02600715</DOC>
	<brief_summary>The purpose of this study is to test whether using belladonna &amp; opiate suppositories (B&amp;Os) can improve patient discomfort during Onabotulinumtoxin A (BoNT) injection into the bladder for treatment of overactive bladder, neurogenic detrusor overactivity, or interstitial cystitis.</brief_summary>
	<brief_title>Reduction of Bladder Injection Pain With Belladonna Opiate Suppository</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Cystitis, Interstitial</mesh_term>
	<mesh_term>Urinary Incontinence, Urge</mesh_term>
	<mesh_term>Urinary Bladder, Neurogenic</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Met clinical criteria under outside care or during the Principal Investigator's routine standard of care for BoNT injection therapy No contraindication to BoNT therapy as outlined by drug manufacturer guidelines Participants have elected to have the BoNT injection therapy prior to being offered enrollment into the study for either overactive bladder (OAB), neurogenic detrusor overactivity (NDO), or refractory interstitial cystitis (IC) Currently pregnant Currently nursing a baby Anticipated geographic relocation within the first 3 months following treatment Allergy to morphine, belladonna, or opiates Patients will be excluded if participating in another research study Individuals unable to provide informed consent or to complete twoweek followup bladder testing (postvoid residual) or data collection will also be excluded</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>